Please assess the completion status of the following clinical trial:

Trial Title: Calcitriol and Dexamethasone Before Radical Prostatectomy in Treating Patients With Localized Adenocarcinoma (Cancer) of the Prostate

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed adenocarcinoma of the prostate~  * Organ-confined disease~ * cT1, cT2, or cT3 tumors~    * Patients with cT1 tumors are eligible if ≥ 1 core biopsies have ≥ 50% of the tumor OR if 50% of the cores examined contain the tumor~ * No small cell carcinoma of the prostate~* Scheduled for radical prostatectomy~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* Not specified~Life expectancy~* Not specified~Hematopoietic~* Platelet count ≥ 100,000/mm\^3~* WBC ≥ 3,500/mm\^3~Hepatic~* ALT and AST ≤ 4 times normal~* Bilirubin ≤ 2 mg/dL~Renal~* Creatinine ≤ 2 times upper limit of normal~* Calcium ≤ 10.5 mg/dL~* No detectable renal stones by CT scan or ultrasound~Other~* No history of diabetes mellitus requiring pharmacotherapy~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* Not specified~Endocrine therapy~* More than 5 years since prior antiestrogens, antiandrogens, luteinizing hormone-releasing hormone agonists, estrogen, or progestational agents~Radiotherapy~* Not specified~Surgery~* See Disease Characteristics~* No prior nephrectomy~* No prior prostatic surgery~* No prior cryotherapy or transurethral resection of the prostate

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Stage 1, Arm I (Type: EXPERIMENTAL): Patients receive oral dexamethasone once daily on days 1-4 and oral calcitriol once daily on days 2-4 weekly for 4 weeks before surgery.
- Stage 1, Arm II (Type: EXPERIMENTAL): No study drugs before surgery.
- Stage 1 Arm 3 (Type: EXPERIMENTAL): Patients receive oral dexamethasone once daily on days 1-4.
- Stage 1, Arm 4 (Type: EXPERIMENTAL): Patients receive oral calcitriol once daily on days 2-4.

Based on this trial design, predict the completion outcome and termination type (if applicable).